
Investing.com -- Johnson & Johnson (NYSE:JNJ) priced shares of its consumer spinoff Kenvue at $20 to $23 apiece in an initial public offering, the company said in a filing Monday.
The consumer health business is seeking to raise about $3.25 billion from the sale of about 151.2 million shares.
Following the completion of the IPO, Johnson & Johnson would continue to own a 91.9% stake in Kenvue, which will trade on the New York Stock Exchange under the ticker “KVUE”.
J&J detailed plans to spin off its consumer health business in late 2021.
The lead underwriters are Goldman Sachs, JP Morgan, BofA Securities, Citigroup, and Deutsche Bank.
JNJ traded roughly flat in after-hours trade on Monday.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.